Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1036805 | 0.94 | REN (0.41) | RENCYP3A4 | |
| SCHEMBL4031262 | 0.91 | REN (0.46) | RENCYP3A4 | |
| SCHEMBL1036809 | 0.89 | REN (0.40) | RENCYP3A4 | |
| SCHEMBL3083192 | 0.88 | REN (0.51) | RENCYP3A4 | |
| SCHEMBL3938967 | 0.87 | REN (0.50) | REN | |
| SCHEMBL4584761 | 0.86 | REN (0.44) | RENCYP3A4 | |
| SCHEMBL4610122 | 0.86 | REN (0.44) | RENCYP3A4 | |
| SCHEMBL3080098 | 0.86 | REN (0.49) | RENCYP3A4 | |
| SCHEMBL4583037 | 0.85 | REN (0.43) | RENCYP3A4 | |
| SCHEMBL4611058 | 0.85 | REN (0.43) | RENCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325947-A1 | NITRATE ESTERS OF PIPERIDINES | NOVARTIS AG (CH) | 2009-12-31 | — | — | US | disclosed |
| EP-2049514-A1 | NITRATE ESTERS OF PIPERIDINES | Speedel Experimenta AG (CH) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008017685-A1 | NITRATE ESTERS OF PIPERIDINES | SPEEDEL EXPERIMENTA AG (CH) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325947-A1 | NITRATE ESTERS OF PIPERIDINES | NOS2, NOS1, NOS3 | REN 29/4885CYP3A4 674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.